Drug Profile
Milatuzumab-doxorubicin conjugate - Immunomedics
Alternative Names: CD-74-DOX; hCD74-DOX; hLL1-DOX; IMMU-110; Milatuzumab-DOXLatest Information Update: 27 Oct 2020
Price :
$50
*
At a glance
- Originator Immunomedics
- Class Antineoplastics; Cytostatic antibiotics; Doxorubicins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA intercalators; MHC class II gene modulators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Chronic lymphocytic leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma
Most Recent Events
- 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
- 12 Mar 2020 Discontinued - Phase-I/II for Chronic lymphocytic leukaemia (Recurrent, Second-line therapy or greater) in USA (IV)
- 12 Mar 2020 Discontinued - Phase-I/II for Multiple myeloma (Second-line therapy or greater) in USA (IV)